

To become certified in the Tolvaptan for ADPKD Shared System REMS to prescribe tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD), you must: complete this Prescriber Knowledge Assessment and the Prescriber Enrollment Form. You must answer ALL eight questions correctly to become certified.

1. Review the following materials:

- Prescribing Information • Program Overview • Prescriber Training

2. Complete your name, NPI number and phone number and answer all 8 questions

3. Submit your completed Prescriber Knowledge Assessment and Prescriber Enrollment Form to the REMS online at www.TolvaptanADPKDSharedREMS.com or via fax at 1-866-750-6820

If completed via fax, you will be notified by the REMS on the status of your certification within 2 business days upon receipt.

When contacted, you will receive either:

- Confirmation of your certification in the REMS or
- Instructions on how to retake the Prescriber Knowledge Assessment, if necessary

**Indicates required field*

Prescriber Information

First Name*: _____ Middle Initial: _____ Last Name*: _____

National Provider Identifier No. (NPI)*: _____ Phone*: _____

Email: _____

Questions 1 - 8 Select the 1 best answer

Question 1

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

- True False

Question 2

Before starting a new patient on tolvaptan for ADPKD, I should:

- Read the U.S. Prescribing Information (USPI), **Prescriber Training**, and the **Program Overview**
- Counsel patients about the risk of serious and potentially fatal liver injury associated with tolvaptan for ADPKD
- Order and review baseline hepatic labs
- All of the above

Question 3

Patients you identify as appropriate for tolvaptan for ADPKD must enroll in the Tolvaptan for ADPKD Shared System REMS in order to be able to receive treatment.

- True False

Question 4

The primary counseling message I should tell my patients is:

- Do not drink alcohol before you take tolvaptan for ADPKD
- Stop therapy if ALT or AST is > 2 times the ULN
- There is a risk of serious and potentially fatal liver injury associated with tolvaptan for ADPKD and that blood testing and monitoring is required
- Patients need to have blood tests every 18 months

Questions 1 – 8 Select the 1 best answer (continued)

Question 5

I will submit a **Patient Status Form** for each patient every 3 months for the first 18 months of treatment and every 6 months thereafter.

- True False

Question 6

I will educate my patients on tolvaptan for ADPKD, the Tolvaptan for ADPKD Shared System REMS, and the signs and symptoms of liver injury and what to do should they experience them, before I enroll them into the Tolvaptan for ADPKD Shared System REMS.

- True False

Question 7

Patients can take tolvaptan for ADPKD and elect not to have blood tests done.

- True False

Question 8

Only pharmacies enrolled in the Tolvaptan for ADPKD Shared System REMS may dispense tolvaptan for ADPKD to patients.

- True False